Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
| ▸ | CFD | P00746 | 1/20 | 0.35 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.34 |
| ▸ | FSCN1 | Q16658 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2160376 | 0.89 | FAAH (0.59) | FAAHF2RL3PTGDR2CFDFSCN1 | |
| SCHEMBL2168840 | 0.81 | FAAH (0.62) | FAAHMAPTSMN1; SMN2 | |
| SCHEMBL2169594 | 0.81 | FAAH (0.66) | FAAHMAPTSMN1; SMN2 | |
| SCHEMBL2160923 | 0.81 | FAAH (0.71) | FAAHF2RL3PTGDR2MAPTRXFP1 | |
| SCHEMBL2169270 | 0.79 | FAAH (0.62) | FAAHF2RL3MAPT | |
| SCHEMBL9958913 | 0.79 | FAAH (0.55) | FAAHF2RL3MAPT | |
| SCHEMBL2167667 | 0.78 | FAAH (0.71) | FAAHMAPTSMN1; SMN2 | |
| SCHEMBL10234721 | 0.78 | FAAH (0.57) | FAAHF2RL3 | |
| SCHEMBL9958914 | 0.76 | FAAH (0.53) | FAAHF2RL3PTGDR2 | |
| SCHEMBL2227880 | 0.74 | FAAH (0.68) | FAAHMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011085216-A2 | USE OF FAAH INHIBITORS FOR TREATING PARKINSON'S DISEASE AND RESTLESS LEGS SYNDROME | IRONWOOD PHARMACEUTICALS, INC. (US) | 2011-07-14 | — | — | WO | disclosed |